This pilot study shows that aliskiren with ACE-inhibitor/ARB therapy allows a clinically significant (22% at month 6) and persistent (up to month 12) decrease in proteinuria. The antiproteinuric effect was at least in part unrelated to the antihypertensive effect and small decrease in eGFR and instead may depend on enhanced suppression of intrarenal angiotensin II with more effective correction of glomerular hypertension.The magnitude of antiproteinuric response was greater in younger patients and those with higher sodium excretion and therefore intake.
Antiproteinuric Response to Add-on Aliskiren in Proteinuric Patients Treated With Dual Blockade of the Renin-Angiotensin System: A 12-Month Prospective Uncontrolled Study / Luca, De Nicola; Pasquale, Zamboli; Vincenzo, Bellizzi; Giovanna, Stanzione; Russo, Domenico; Felice, Nappi; Maristella, Minco; Paolo, Chiodini; Giuseppe, Conte; Roberto, Minutolo. - In: AMERICAN JOURNAL OF KIDNEY DISEASES. - ISSN 0272-6386. - 57:6(2011), pp. 961-963. [10.1053/j.ajkd.2011.02.384]
Antiproteinuric Response to Add-on Aliskiren in Proteinuric Patients Treated With Dual Blockade of the Renin-Angiotensin System: A 12-Month Prospective Uncontrolled Study
RUSSO, DOMENICO;
2011
Abstract
This pilot study shows that aliskiren with ACE-inhibitor/ARB therapy allows a clinically significant (22% at month 6) and persistent (up to month 12) decrease in proteinuria. The antiproteinuric effect was at least in part unrelated to the antihypertensive effect and small decrease in eGFR and instead may depend on enhanced suppression of intrarenal angiotensin II with more effective correction of glomerular hypertension.The magnitude of antiproteinuric response was greater in younger patients and those with higher sodium excretion and therefore intake.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
